# Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

> **NCT06915025** · PHASE3 · RECRUITING · sponsor: **Imunon** · enrollment: 500 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Olaparib
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT06915025
- **Lead sponsor:** Imunon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-09
- **Primary completion:** 2032-10-31
- **Final completion:** 2032-10-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06915025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06915025, "Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06915025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*